MX373876B - 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. - Google Patents

1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.

Info

Publication number
MX373876B
MX373876B MX2017013853A MX2017013853A MX373876B MX 373876 B MX373876 B MX 373876B MX 2017013853 A MX2017013853 A MX 2017013853A MX 2017013853 A MX2017013853 A MX 2017013853A MX 373876 B MX373876 B MX 373876B
Authority
MX
Mexico
Prior art keywords
disorder
gpr52
treatment
compounds
pharmaceutical compositions
Prior art date
Application number
MX2017013853A
Other languages
English (en)
Spanish (es)
Other versions
MX2017013853A (es
Inventor
Albert S Ren
Andrew J Grottick
Didier Jc Bagnol
Graeme Semple
Henry Korman
Juerg Lehmann
Yifeng Xiong
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2017013853A publication Critical patent/MX2017013853A/es
Publication of MX373876B publication Critical patent/MX373876B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MX2017013853A 2015-04-29 2016-04-29 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. MX373876B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154523P 2015-04-29 2015-04-29
PCT/US2016/030105 WO2016176571A1 (en) 2015-04-29 2016-04-29 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto

Publications (2)

Publication Number Publication Date
MX2017013853A MX2017013853A (es) 2018-06-07
MX373876B true MX373876B (es) 2020-03-26

Family

ID=56015108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013853A MX373876B (es) 2015-04-29 2016-04-29 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.

Country Status (15)

Country Link
US (1) US9676758B2 (enExample)
EP (1) EP3292114B1 (enExample)
JP (1) JP6673939B2 (enExample)
KR (1) KR20180004193A (enExample)
CN (1) CN108174603B (enExample)
AU (1) AU2016255510A1 (enExample)
BR (1) BR112017022987A2 (enExample)
CA (1) CA2984153A1 (enExample)
CL (1) CL2017002738A1 (enExample)
EA (1) EA034244B1 (enExample)
ES (1) ES2784316T3 (enExample)
IL (1) IL255185A0 (enExample)
MX (1) MX373876B (enExample)
PH (1) PH12017501961A1 (enExample)
WO (1) WO2016176571A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
BR112022008685A2 (pt) 2019-11-08 2022-07-26 Heptares Therapeutics Ltd Compostos moduladores de gpr52
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
PE20221918A1 (es) * 2020-03-30 2022-12-29 Boehringer Ingelheim Int 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
US12421193B2 (en) 2020-04-22 2025-09-23 Neurocrine Biosciences, Inc. GPR52 modulators and methods of use
GB202013558D0 (en) * 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds
EP4330232A1 (en) 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN117940420A (zh) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
TW202425979A (zh) * 2022-10-26 2024-07-01 美商紐羅克里生物科學有限公司 作為gpr52調節劑之化合物及組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043744A2 (en) * 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2298731A4 (en) * 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
UY32045A (es) 2008-08-12 2010-03-26 Takeda Pharmaceutical Compuesto amida
JP2012530758A (ja) * 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
JP2012082175A (ja) * 2010-10-14 2012-04-26 Daiichi Sankyo Co Ltd インドリン化合物を含有する医薬組成物

Also Published As

Publication number Publication date
EP3292114A1 (en) 2018-03-14
EA034244B1 (ru) 2020-01-21
AU2016255510A1 (en) 2017-11-23
EP3292114B1 (en) 2020-03-11
ES2784316T3 (es) 2020-09-24
CN108174603B (zh) 2021-07-02
PH12017501961A1 (en) 2018-03-26
IL255185A0 (en) 2017-12-31
CA2984153A1 (en) 2016-11-03
CL2017002738A1 (es) 2018-06-01
WO2016176571A1 (en) 2016-11-03
CN108174603A (zh) 2018-06-15
KR20180004193A (ko) 2018-01-10
EA201792375A1 (ru) 2018-05-31
JP6673939B2 (ja) 2020-04-01
JP2018519253A (ja) 2018-07-19
US20160318911A1 (en) 2016-11-03
US9676758B2 (en) 2017-06-13
MX2017013853A (es) 2018-06-07
BR112017022987A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
PH12017501961A1 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
UY36037A (es) Derivados de indazol y 2-metil-pirazol-piridina sustituidos como inhibidores de la tirosina quinasa (syk) del bazo y composiciones farmacéuticas que las contienen
BR112017007794A2 (pt) proteínas tóxicas ou inibitórias inseticidas quiméricas para pragas lepidópteros
UY35225A (es) Lactamas Fusionadas de Arilo y Heteroarilo
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA201500402A1 (ru) Гетероароматические соединения в качестве лигандов допамина d1
MX2018004923A (es) Aceite de sabadilla.
MX388390B (es) Preparacion de lote maestro a base de azufre y nano-rellenadores carbonosos, lote maestro producido, y usos del mismo.
BR112018014902A2 (pt) plantas partenocárpicas do tipo solanácea, frutos e sementes de uma planta, produtos processados comestíveis, métodos de produção e de reprodução de uma planta,
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX380149B (es) Metodo para la inactivación continua de un virus en un microreactor
ATE471933T1 (de) Neue imidazolderivate, ihre herstellung und ihre verwendung als medizin
MY183011A (en) Novel purification process of gonadotropin
MX2017014872A (es) Metodos para preparar factor de von willebrand modificado.
PH12017501872A1 (en) Methods of treating diseases
AR130864A1 (es) Compuestos y composiciones como moduladores de gpr52
MX2018004174A (es) Control biologico de virus vegetales.
CL2018001455A1 (es) Composición para control de enfermedades de plantas, y método de control de enfermedades de plantas
CO7160011A2 (es) Compuestos de azetidina y piperidina útiles como inhibidores de pde10
REN Chemical constituents from Scilla scilloides
AR130866A1 (es) Compuestos y composiciones como moduladores de gpr52
FR3022378B1 (fr) Procede de maintenance, en particulier preventive, d'un appareil non informatique tel qu'un appareil de cuisine
EA201692179A1 (ru) Способ биохимической денатурации асбестосодержащего материала
LIANG et al. Applicationof" blendsign" onCTpredictingearlyhaematomaexpansioninacuteintracerebralhaemorrhage

Legal Events

Date Code Title Description
FG Grant or registration